HONG KONG – Boehringer Ingelheim GmbH and China Southeast University Institute of Life Sciences are spearheading a research project to develop new treatments for hearing loss through regeneration of hair cells from inner ear stem cells.
HONG KONG – Boehringer Ingelheim GmbH and China Southeast University Institute of Life Sciences are spearheading a research project to develop new treatments for hearing loss through regeneration of hair cells from inner ear stem cells.
HONG KONG – Singapore is becoming a hotbed for stem cell research. And a recent breakthrough involving a stem cell treatment for diabetic wounds, developed by Cellresearch Corp. Pte. Ltd., could further cement the nation’s reputation as a leader in biomedical innovation.
HONG KONG – Singapore is becoming a hotbed for stem cell research. And a recent breakthrough involving a stem cell treatment for diabetic wounds, developed by Cellresearch Corp. Pte. Ltd., could further cement the nation's reputation as a leader in biomedical innovation.
HONG KONG – China's health care sector is seeing a surge of mergers and acquisitions thanks to regulatory reforms that are expected to drive development. Case in point is Sciclone Pharmaceuticals Inc., a San Francisco-based drug developer that markets drugs in China. The company confirmed this month that it received an unsolicited $570 million acquisition offer.
HONG KONG – China's health care sector is seeing a surge of mergers and acquisitions thanks to regulatory reforms that are expected to drive development. Case in point is Sciclone Pharmaceuticals Inc., a San Francisco-based drug developer that markets drugs in China. The company confirmed this month that it received an unsolicited $570 million acquisition offer.
